Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Sep;37(5):286–292. doi: 10.1007/BF01518450

Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor

Eitan Shiloni 1, Stephen E Karp 1, Mary C Custer 1, Joel Shilyansky 1, Nicholas P Restifo 1,✉, Steven A Rosenberg 1, James J Mulé 1
PMCID: PMC2248452  NIHMSID: NIHMS38283  PMID: 8402732

Abstract

Gene modification of tumor cells with the cDNA for interferon γ (IFNγ) has been shown to increase the immunogenicity of some tumor cells. In order to explore further the possible therapeutic relevance of these previous findings, two clones of the nonimmunogenic MCA-102 fibrosarcoma of C57BL/6 origin were retrovirally transduced with the cDNA encoding murine IFNγ: 102.4JK (4JK), a clone with relatively high major histocompatibility complex (MHC) class I expression, and 102.24JK (24JK), a clone with low expression of surface MHC class I molecules. Retroviral transduction of tumor cells with the cDNA encoding for IFNγ resulted in a substantial up-regulation of MHC class I surface expression in the 24JK clone but little change of class I in the 4JK clone. In an attempt to generate antitumor lymphocytes, these gene-modified cells were inoculated into mouse footpads and draining lymph nodes (DLN) were removed, dispersed, and cultured in vitro for 10 days with irradiated tumor cells and interleukin-2. DLN from mice bearing either unmodified tumor or tumor transduced with cDNA encoding neomycin resistance (Neo R) or IFNγ, were used to treat recipients harboring 3-day pulmonary metastases induced by the parental, unmodified tumor. Treatment with DLN cells obtained following the injection of 24JK tumor cells modified with the gene for IFNγ significantly reduced the number of pulmonary metastases in four separate experiments, compared to groups treated by DLN cells generated from inoculation of either the unmodified, parental 24JK clone or the same clone transduced with theNeo R gene only. In contrast, DLN cells induced either by IFNγ-transduced 4JK (high expression of MHC class I) or an unmodified 4JK tumor (moderate expression of MHC class I) had significant but equal therapeutic efficacy. Although the in vitro growth rate of tumor cell lines was unaffected by the insertion of the mouse IFNγ cDNA, their in vivo (s.c.) growth rates were significantly slower than those of the nontransduced tumors. Thus, after retroviral transduction of the murine IFNγ cDNA into a nonimmunogenic tumor with a very low level of surface expression of MHC class I, modified tumor cells could elicit therapeutic T cells from DLN capable of successfully treating established pulmonary metastases upon adoptive transfer. This strategy significantly confirms previous observations on the potential therapeutic effects of gene modification of tumor cells with IFNγ and extends the realm of therapeutic possibilities to include the use of DLN cells for the development of T-cell based immunotherapies against nonimmunogenic human tumors.

Key words: Draining lymph nodes, T cells, Gene modification, Immunotherapy, Interferon γ

References

  • 1.Bahram S, Arnold D, Bresnahan M, Strominger JL, Spies T. Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc Natl Acad Sci USA. 1991;88:10094. doi: 10.1073/pnas.88.22.10094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Brown MC, Driscoll J, Monaco JJ. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature. 1991;353:355. doi: 10.1038/353355a0. [DOI] [PubMed] [Google Scholar]
  • 3.van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]
  • 4.Carlow DA, Kerbel RS, Elliot BE. Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. J Natl Cancer Inst. 1989;81:759. doi: 10.1093/jnci/81.10.759. [DOI] [PubMed] [Google Scholar]
  • 5.Christinck RE, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature. 1991;352:67. doi: 10.1038/352067a0. [DOI] [PubMed] [Google Scholar]
  • 6.Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC. MHC class II region encoding proteins related to the multidrug resistance family of trans-membrane transporters. Nature. 1990;348:738. doi: 10.1038/348738a0. [DOI] [PubMed] [Google Scholar]
  • 7.Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-γ, tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1) J Immunol. 1986;137:245. [PubMed] [Google Scholar]
  • 8.Dustin ML, Singer KH, Tuck DT, Springer TA. Adhesions of T lymphoblasts to epidermal keratinocytes is regulated by interferongamma and is mediated by intra-cellular adhesions molecule 1 (ICAM-1) J Exp Med. 1988;167:1323. doi: 10.1084/jem.167.4.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Elliot BE, Carlow DA, Rodricks A, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res. 1989;53:181. doi: 10.1016/s0065-230x(08)60282-1. [DOI] [PubMed] [Google Scholar]
  • 10.Fox BA, Spiess PJ, Kasid A, Puri R, Mulé JJ, Weber JS, Rosenberg SA. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod. 1990;9:499. [PubMed] [Google Scholar]
  • 11.Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Research. 1990;50:7820. [PubMed] [Google Scholar]
  • 12.Glynne R, Powis SH, Bech S, Kelly A, Kerr L-A, Trowsdale J. A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature. 1991;353:357. doi: 10.1038/353357a0. [DOI] [PubMed] [Google Scholar]
  • 13.Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. Nature. 1992;357:375. doi: 10.1038/357375a0. [DOI] [PubMed] [Google Scholar]
  • 14.Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281. doi: 10.1016/s0065-2776(08)60778-6. [DOI] [PubMed] [Google Scholar]
  • 15.Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature. 1984;311:750. doi: 10.1038/311750a0. [DOI] [PubMed] [Google Scholar]
  • 16.Kruskel WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Statist Assoc. 1952;47:583. [Google Scholar]
  • 17.LeGrue S, Ananthaswamy H, Simeik J. Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids. Cancer Res. 1989;49:4747. [PubMed] [Google Scholar]
  • 18.Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980. [PMC free article] [PubMed] [Google Scholar]
  • 19.Monaco JJ, Cho S, Attaya M. Transport protein genes in the murine MHC: possible implications for antigen processing. Nature. 1990;250:1723. doi: 10.1126/science.2270487. [DOI] [PubMed] [Google Scholar]
  • 20.Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225:1487. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  • 21.Mulé JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol. 1987;139:285. [PubMed] [Google Scholar]
  • 22.Powis SJ, Deverson EV, Coadwell WJ, Ciruela A, Huskisson NS, Smith H, Butcher GW, Howard JC. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature. 1992;357:211. doi: 10.1038/357211a0. [DOI] [PubMed] [Google Scholar]
  • 23.Restifo NP. Antigen processing and presentation: an update. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer updates. Philadelphia: Lippincott; 1992. p. 1. [Google Scholar]
  • 24.Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mulé JJ, Yewdell JW, Rosenberg SA. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an antitumor immune response. J Immunol. 1991;147:1453. [PMC free article] [PubMed] [Google Scholar]
  • 25.Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferongamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423. doi: 10.1084/jem.175.6.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265. doi: 10.1084/jem.177.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rosenberg SA, Packard BS, Aebersold PM, Dolomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 28.Schreiber H, Ward PL, Rowley DA, Stauss HJ. Unique tumor-specific antigens. Annu Rev Immunol. 1988;6:465. doi: 10.1146/annurev.iy.06.040188.002341. [DOI] [PubMed] [Google Scholar]
  • 29.Shu SY, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol. 1989;143:740. [PubMed] [Google Scholar]
  • 30.Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature. 1990;348:744. doi: 10.1038/348744a0. [DOI] [PubMed] [Google Scholar]
  • 31.Tanaka K, Isselbacher KJ, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science. 1985;228:26. doi: 10.1126/science.3975631. [DOI] [PubMed] [Google Scholar]
  • 32.Tanaka K, Hayashi H, Hamada C, Khoury G, Jay G. Expression of major histocompatability complex class I antigens as a strategy for the potentiation of the immune recognition of tumor cells. Proc Natl Acad Sci USA. 1986;83:8723. doi: 10.1073/pnas.83.22.8723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters. Nature. 1990;348:741. doi: 10.1038/348741a0. [DOI] [PubMed] [Google Scholar]
  • 34.Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med. 1991;173:1373. doi: 10.1084/jem.173.6.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wallich W, Bulbuc N, Hämmerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumor cells by de novo expression of H-2 K antigens following H-2 gene transfection. Nature. 1985;315:301. doi: 10.1038/315301a0. [DOI] [PubMed] [Google Scholar]
  • 36.Wantanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E-I, Taniyama T, Sakata T-A. Exogenous expression of mouse interferon γ cDNA in mouse neuro-blastoma C1300 cells results in reduced tumorigenicity by aumented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86:9456. doi: 10.1073/pnas.86.23.9456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Weber JS, Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988;48:5818. [PubMed] [Google Scholar]
  • 38.Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med. 1987;166:1716. doi: 10.1084/jem.166.6.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Weis JH, Seidman The expression of major histo-compatibility antigens under metallothionein gene promoter control. J Immunol. 1985;134:1999. [PubMed] [Google Scholar]
  • 40.Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to MHC class I molecule-restricted T lymphocytes. Annu Rev Immunol. 1992;52:1. doi: 10.1016/s0065-2776(08)60875-5. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES